81 related articles for article (PubMed ID: 10885610)
1. Opposite effects of antimicrotubule agents on c-myc oncogene expression depending on the cell lines used.
Bourgarel-Rey V; El Khyari S; Rimet O; Bordas B; Guigal N; Braguer D; Seree E; Barra Y; Briand C
Eur J Cancer; 2000 May; 36(8):1043-9. PubMed ID: 10885610
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment by tubulin agents decreases C-MYC induction in human colon carcinoma cell line HT29-D4.
el Khyari S; Bourgarel V; Barra Y; Braguer D; Briand C
Biochem Biophys Res Commun; 1997 Feb; 231(3):751-4. PubMed ID: 9070886
[TBL] [Abstract][Full Text] [Related]
3. Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors.
Bourgarel-Rey V; Vallee S; Rimet O; Champion S; Braguer D; Desobry A; Briand C; Barra Y
Mol Pharmacol; 2001 May; 59(5):1165-70. PubMed ID: 11306700
[TBL] [Abstract][Full Text] [Related]
4. Quantification of changes in c-myc mRNA levels in normal human bronchial epithelial (NHBE) and lung adenocarcinoma (A549) cells following chemical treatment.
Fields WR; Desiderio JG; Putnam KP; Bombick DW; Doolittle DJ
Toxicol Sci; 2001 Sep; 63(1):107-14. PubMed ID: 11509750
[TBL] [Abstract][Full Text] [Related]
5. Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: relation to c-myc-oncogene and vitamin-D-receptor expression.
Hulla W; Kállay E; Krugluger W; Peterlik M; Cross HS
Int J Cancer; 1995 Sep; 62(6):711-6. PubMed ID: 7558419
[TBL] [Abstract][Full Text] [Related]
6. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
Wang HL; Wang J; Xiao SY; Haydon R; Stoiber D; He TC; Bissonnette M; Hart J
Int J Cancer; 2002 Oct; 101(4):301-10. PubMed ID: 12209953
[TBL] [Abstract][Full Text] [Related]
7. CpG hypermethylation of the C-myc promoter by dsRNA results in growth suppression.
Mehndiratta M; Palanichamy JK; Pal A; Bhagat M; Singh A; Sinha S; Chattopadhyay P
Mol Pharm; 2011 Dec; 8(6):2302-9. PubMed ID: 21879731
[TBL] [Abstract][Full Text] [Related]
8. Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene.
Forgue-Lafitte ME; Coudray AM; Bréant B; Mester J
Cancer Res; 1989 Dec; 49(23):6566-71. PubMed ID: 2684395
[TBL] [Abstract][Full Text] [Related]
9. Over-expression and amplification of the c-myc gene in human urothelial carcinoma.
Christoph F; Schmidt B; Schmitz-Dräger BJ; Schulz WA
Int J Cancer; 1999 Apr; 84(2):169-73. PubMed ID: 10096250
[TBL] [Abstract][Full Text] [Related]
10. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
11. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
13. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc.
Zhu GH; Wong BC; Eggo MC; Ching CK; Yuen ST; Chan EY; Lai KC; Lam SK
Br J Cancer; 1999 Feb; 79(3-4):393-400. PubMed ID: 10027304
[TBL] [Abstract][Full Text] [Related]
14. miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.
Guo X; Zhu Y; Hong X; Zhang M; Qiu X; Wang Z; Qi Z; Hong X
Cell Death Dis; 2017 Jul; 8(7):e2958. PubMed ID: 28749470
[TBL] [Abstract][Full Text] [Related]
15. c-Myc overexpression and endocrine resistance in breast cancer.
McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
[TBL] [Abstract][Full Text] [Related]
16. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
Russo P; Arzani D; Trombino S; Falugi C
J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.
Tselepis C; Perry I; Dawson C; Hardy R; Darnton SJ; McConkey C; Stuart RC; Wright N; Harrison R; Jankowski JA
Oncogene; 2002 Sep; 21(39):6071-81. PubMed ID: 12203119
[TBL] [Abstract][Full Text] [Related]
19. Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Suenaga M; Yamamoto M; Tabata S; Itakura S; Miyata M; Hamasaki S; Furukawa T
Anticancer Res; 2013 Apr; 33(4):1547-54. PubMed ID: 23564796
[TBL] [Abstract][Full Text] [Related]
20. Effects of sodium butyrate on the rearranged c-myc expression in mouse plasmacytoma cells.
Kondoh N; Oikawa T; Satoh C; Kuzumaki N
Exp Cell Res; 1991 Sep; 196(1):146-9. PubMed ID: 1879469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
